Showing results (461-470 of 3,194) with videos related to
Sort By:
Pageof 320
The Journal of the Louisiana State Medical Society : Official Organ of the Louisiana State Medical Society|August 1, 1996
Lafayette's family practice residency program: practice patterns of graduatesG N Jones, A C ReesJournal of Clinical Microbiology|July 1, 1989
Comparison of cefadroxil and cephalothin disk susceptibility test resultsA L Barry, R N JonesThe Nursing Clinics of North America|September 4, 2013
Underage drinking: an evolutionary concept analysisSandra N Jones, Roberta L WaiteThe Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|November 6, 2014
Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012Robert P Rennie, Ronald N JonesClinical Therapeutics|January 15, 2021
Targeting the Dysfunctional Placenta to Improve Pregnancy Outcomes Based on Lessons Learned in CancerRebecca L Wilson, Helen N JonesJournal of Clinical Microbiology|October 1, 1987
Reliability of high-content disks and modified broth dilution tests for detecting staphylococcal resistance to the penicillinase-resistant penicillinsA L Barry, R N JonesEuropean Journal of Clinical Microbiology|April 1, 1987
Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility testA L Barry, R N JonesJournal of Clinical Microbiology|November 1, 1987
Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporinR N Jones, A L BarryDiagnostic Microbiology and Infectious Disease|November 1, 1989
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830)R N Jones, A L BarryDiagnostic Microbiology and Infectious Disease|January 1, 1988
BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolatesR N Jones, A L BarryPageof 320